Subtopic Deep Dive
Hepatic Angiosarcoma Pathogenesis and Treatment
Research Guide
What is Hepatic Angiosarcoma Pathogenesis and Treatment?
Hepatic angiosarcoma is a rare, aggressive malignant vascular tumor of the liver linked to exposures like vinyl chloride and thorotrast, characterized by rapid progression and poor prognosis despite multimodal treatments.
Research identifies key etiologies including vinyl chloride (Thomas et al., 1975, 200 citations) and thorotrast (Ito et al., 1988, 118 citations), with genomic alterations in p53 and PIK3CA/AKT/mTOR pathways (Italiano et al., 2012, 121 citations). Treatment studies highlight weekly paclitaxel efficacy in unresectable cases (Penel et al., 2008, 680 citations) and assess outcomes from chemotherapy and transplantation (Zheng et al., 2013, 119 citations). Over 10 major papers span epidemiology to therapy, with ~2,000 combined citations.
Why It Matters
Hepatic angiosarcoma informs occupational health policies due to vinyl chloride links, as Falk et al. (1981, 121 citations) surveyed 168 U.S. cases tied to industrial exposure. Advances in paclitaxel therapy from Penel et al. (2008, 680 citations) guide sarcoma management, improving unresectable angiosarcoma responses. Prognostic insights from Locker et al. (1979, 267 citations) and Kim et al. (2009, 113 citations) shape liver transplantation decisions, impacting rare tumor care amid 2-3% sarcoma incidence.
Key Research Challenges
Etiology Identification
Linking exposures like vinyl chloride to angiosarcoma requires historical cohort analysis, as Thomas et al. (1975) found angiosarcomas in 15/20 exposed workers. Challenges persist in detecting rare non-occupational cases (Falk et al., 1981). Modern epidemiology needs larger datasets beyond 168-case surveys.
Genomic Profiling
p53 and PIK3CA/AKT/mTOR alterations drive pathogenesis (Italiano et al., 2012), but complex sarcoma genomics hinders targeted therapies. Profiling rare hepatic cases lags behind other sarcomas. Validation across small cohorts remains inconsistent.
Effective Treatments
Paclitaxel shows response in ANGIOTAX trial (Penel et al., 2008), yet overall survival is poor (Zheng et al., 2013). Neoadjuvant chemotherapy and transplantation outcomes vary (Kim et al., 2009). Multimodal trials face recruitment barriers due to rarity.
Essential Papers
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
Nicolas Penel, Binh Bui, Jacques‐Olivier Bay et al. · 2008 · Journal of Clinical Oncology · 680 citations
Purpose The objective of this phase II trial was to assess the efficacy and toxicity of weekly paclitaxel for patients with metastatic or unresectable angiosarcoma. Patients and Methods Thirty pati...
The Clinical Features of Hepatic Angiosarcoma: A Report of Four Cases and A Review of the English Literature
Gershon Y. Locker, James H. Doroshow, Leonard A. Zwelling et al. · 1979 · Medicine · 267 citations
Four cases of hepatic angiosarcoma are reported with a review of 99 other cases in the English literature. Angiosarcoma of the liver is associated with chronic exposure to thorotrast, vinyl chlorid...
Vinyl-Chloride-Induced Liver Disease
Louis B. Thomas, Hans Pópper, Paul D. Berk et al. · 1975 · New England Journal of Medicine · 200 citations
Histologic examination of liver tissue (eight autopsy and 18 biopsy specimens) and five spleens from 20 workers with vinyl chloride polymerization showed hepatic angiosarcomas in 15. In addition, a...
Splenic Angiosarcoma: A Clinicopathologic and Immunophenotypic Study of 28 Cases
Thomas S. Neuhauser, Gregory A. Derringer, Lester D.�R. Thompson et al. · 2000 · Modern Pathology · 197 citations
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas
Antoîne Italiano, Chun‐Liang Chen, Rachael Thomas et al. · 2012 · Cancer · 121 citations
Abstract BACKGROUND: The p53 and phosphoinositide‐3‐kinase, catalytic, alpha polypeptide/v‐akt murine thymoma viral oncogene homolog/mechanistic target of rapamycin (PIK3CA/AKT/mTOR) pathways frequ...
Epidemiology of hepatic angiosarcoma in the United States: 1964-1974.
Henry Falk, John J. Herbert, Steven D. Crowley et al. · 1981 · Environmental Health Perspectives · 121 citations
A nationwide survey of hepatic angiosarcoma (HAS) in the United States during the years 1964 through 1974 identified 168 cases. Of these, 42 cases (25%) were associated with known etiologic factors...
Overexpression of VEGF 121 in Immortalized Endothelial Cells Causes Conversion to Slowly Growing Angiosarcoma and High Level Expression of the VEGF Receptors VEGFR-1 and VEGFR-2 in Vivo
Jack L. Arbiser, Helena Larsson, Lena Claesson‐Welsh et al. · 2000 · American Journal Of Pathology · 119 citations
Reading Guide
Foundational Papers
Start with Locker et al. (1979, 267 citations) for clinical features and etiology review of 99 cases; Thomas et al. (1975, 200 citations) for vinyl chloride pathology; Penel et al. (2008, 680 citations) for paclitaxel trial establishing treatment benchmarks.
Recent Advances
Italiano et al. (2012, 121 citations) on p53/PIK3CA pathways; Zheng et al. (2013, 119 citations) on primary hepatic options; Kim et al. (2009, 113 citations) on advanced stage outcomes.
Core Methods
Epidemiology via cohort surveys (Falk 1981); histopathology and immunohistochemistry (Locker 1979; Neuhauser 2000); phase II trials like ANGIOTAX (Penel 2008); genomic sequencing for p53/PIK3CA (Italiano 2012).
How PapersFlow Helps You Research Hepatic Angiosarcoma Pathogenesis and Treatment
Discover & Search
Research Agent uses searchPapers and exaSearch to find vinyl chloride etiology papers like Thomas et al. (1975), then citationGraph reveals Falk et al. (1981) connections, and findSimilarPapers uncovers related thorotrast studies (Ito et al., 1988).
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival data from Penel et al. (2008), verifies claims with CoVe against Italiano et al. (2012) genomics, and runs PythonAnalysis for meta-analysis of response rates across 680-citation trials using GRADE grading for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in transplantation outcomes post-Penel et al. (2008), flags contradictions between Locker et al. (1979) and Kim et al. (2009); Writing Agent uses latexEditText, latexSyncCitations for ANGIOTAX review, and latexCompile for prognosis tables with exportMermaid diagrams.
Use Cases
"Analyze survival rates from paclitaxel trials in hepatic angiosarcoma using Python."
Research Agent → searchPapers('paclitaxel angiosarcoma') → Analysis Agent → readPaperContent(Penel 2008) → runPythonAnalysis(pandas meta-analysis of 30-patient cohort) → GRADE-verified survival curves output.
"Draft LaTeX review on vinyl chloride pathogenesis with citations."
Research Agent → citationGraph(Thomas 1975) → Synthesis Agent → gap detection → Writing Agent → latexEditText('pathogenesis section') → latexSyncCitations(Falk 1981, Thomas 1975) → latexCompile → PDF review.
"Find code for angiosarcoma genomic analysis from papers."
Research Agent → searchPapers('p53 PIK3CA angiosarcoma') → Code Discovery → paperExtractUrls(Italic 2012) → paperFindGithubRepo → githubRepoInspect → R/Bioconductor scripts for pathway analysis.
Automated Workflows
Deep Research workflow scans 50+ angiosarcoma papers via searchPapers, structures etiology report chaining citationGraph from Thomas (1975) to Falk (1981). DeepScan applies 7-step CoVe to verify Penel (2008) paclitaxel efficacy with GRADE checkpoints. Theorizer generates hypotheses on PIK3CA/mTOR targeting from Italiano (2012) literature synthesis.
Frequently Asked Questions
What defines hepatic angiosarcoma pathogenesis?
Rare liver vascular tumor driven by vinyl chloride (Thomas et al., 1975) and thorotrast (Ito et al., 1988), with p53/PIK3CA alterations (Italiano et al., 2012).
What are key treatment methods?
Weekly paclitaxel for unresectable cases (Penel et al., 2008, 680 citations); neoadjuvant chemo and transplantation assessed (Kim et al., 2009; Zheng et al., 2013).
What are seminal papers?
Penel et al. (2008, 680 citations) on paclitaxel; Locker et al. (1979, 267 citations) clinical review; Thomas et al. (1975, 200 citations) on vinyl chloride.
What open problems exist?
Targeted therapies for genomic drivers (Italiano et al., 2012); improving transplantation outcomes (Zheng et al., 2013); expanding epidemiology beyond occupational exposures (Falk et al., 1981).
Research Vascular Tumors and Angiosarcomas with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hepatic Angiosarcoma Pathogenesis and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Vascular Tumors and Angiosarcomas Research Guide